Final - February 17, 2023 

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) 

Centers for Disease Control and Prevention 

Atlanta, Georgia 30329 

February 22-24, 2023 

Wednesday, February 22, 2023 

8:00 Welcome & Introductions Dr. Grace Lee (ACIP, Chair) 

Dr. Melinda Wharton (ACIP Executive Secretary, CDC) 

8:30 Mpox Vaccine 

Introduction 

Epidemiology of mpox during 2022 outbreak in the United States 

JYNNEOS vaccine safety 

JYNNEOS vaccine effectiveness 

Mpox vaccine acceptability and uptake from cross-sectional surveys 

Interim clinical considerations 

EtR: Use of JYNNEOS during mpox outbreaks 

Dr. Pablo Sanchez (ACIP, WG Chair) 

Dr. Sascha Ellington (CDC/NCCDPHP) 

Dr. Jonathan Duffy (CDC/NCEZID) 

Dr. Anna Chard (CDC/NCIRD) 

Dr. Kevin P. Delaney (CDC/NCHHSTP) 

Dr. Rosalind Carter (CDC/NCIRD) 

Dr. Agam Rao (CDC/NCEZID) 

11:30 Break 

12:30 Respiratory disease surge, Fall 2022, United States Dr. José R. Romero (CDC, Director NCIRD) 

1:00 Influenza Vaccine 

Introduction 

U.S. Influenza activity update 

Preliminary 2022-23 influenza vaccine effectiveness: CDC networks 

Preliminary 2022-23 influenza vaccine effectiveness: Wisconsin 

Dr. Keipp Talbot (ACIP, WG Chair) 

Dr. Lisa Grohskopf (CDC/NCIRD) 

Ms. Samantha Olson, Dr. Nathaniel Lewis, Dr. Mark 

Tenforde (CDC/NCIRD) 

Dr. Huong McLean, Marshfield Clinic Research Institute 

1:50 Break 

2:00 Public Comment 

2:30 VOTES 

Mpox Dr. Agam Rao (CDC/NCEZID) 

2:50 Break 

3:00 Pneumococcal Vaccines 

Introduction 

Epidemiology of pneumococcal disease among U.S. children 

Estimating the impact of higher-valency PCVs on pediatric outpatient ARI 

visits and antibiotic use 

PCV20 Phase 2/3 study results among children 

Preliminary EtR (incl. GRADE) for PCV20 use in U.S. children 

Workgroup considerations 

Dr. Katherine Poehling (ACIP, WG Chair) 

Mr. Ryan Gierke (CDC/NCIRD) 

Ms. Laura King (UC Berkeley) 

Dr. Wendy Watson (Pfizer) 

Dr. Miwako Kobayashi (CDC/NCIRD) 

Dr. Miwako Kobayashi (CDC/NCIRD) 

5:00 Adjourn 

Thursday, February 23, 2023 

8:00 Welcome & Introductions Dr. Grace Lee (ACIP, Chair) 

Dr. Melinda Wharton (ACIP Executive Secretary, CDC) 

8:10 Agency Updates 

CDC, CMS, FDA, HRSA, IHS, OIDP, NIH 

8:30 Meningococcal Vaccines 

Introduction 

Epidemiology of meningococcal disease in the United States 

Pfizer pentavalent meningococcal vaccine 

Workgroup considerations 

Dr. Kathy Poehling (ACIP, WG Chair) 

Ms. Amy Rubis (CDC/NCIRD) 

Dr. Jason Maguire (Pfizer) 

Dr. Sam Crowe (CDC/NCIRD) 

9:30 Polio Vaccine 

Introduction Dr. Oliver Brooks (ACIP, WG Chair) 

Recommendations for Adult Polio Vaccination Dr. Sarah Kidd (CDC/NCIRD) 

10:00 Break 
Final - February 17, 2023 

10:20 RSV Vaccines - Pediatric/Maternal 

Introduction 

Cost effectiveness analysis for nirsevimab – CDC model 

Cost effectiveness analysis for nirsevimab – Comparison to manufacturer 

model 

Evidence to Recommendations framework for nirsevimab 

Clinical considerations for nirsevimab 

Safety and Efficacy of RSV Bivalent PreF Maternal Vaccine 

Workgroup considerations 

Dr. Sarah Long (ACIP, WG Chair) 

Dr. David Hutton (University of Michigan) 

Dr. Ismael Ortega Sanchez (CDC/NCIRD) 

Dr. Jefferson Jones (CDC/NCIRD) 

Dr. Jefferson Jones (CDC/NCIRD) 

Dr. Iona Munjal (Pfizer) 

Dr. Katherine Fleming-Dutra (CDC/NCIRD) 

12:20 Break 

1:20 RSV Vaccines - Adult 

Introduction 

Cost effectiveness of the GSK and Pfizer vaccines (main CDC model) 

Comparison of cost effectiveness results of the main CDC model and each 

manufacturer model (GSK & Pfizer) 

EtR (incl. GRADE) for 2 vaccines (GSK & Pfizer) 

Vaccine policy questions (GSK & Pfizer) 

Dr. Camille Kotton (ACIP, WG Chair) 

Dr. David Hutton (University of Michigan) 

Dr. Ismael Ortega Sanchez (CDC/NCIRD) 

Dr. Michael Melgar (CDC/NCIRD) 

Dr. Michael Melgar (CDC/NCIRD) 

3:05 Break 

3:25 Chikungunya Vaccine 

Introduction 

Global epidemiology of chikungunya 

Chikungunya in U.S. travelers 

Persistent arthralgia following chikungunya 

Workgroup considerations 

Dr. Beth Bell (ACIP, WG Chair) 

Dr. Susan Hills (CDC/NCEZID) 

Ms. Nicole Lindsey (CDC/NCEZID) 

Ms. Nicole Lindsey (CDC/NCEZID) 

Ms. Nicole Lindsey (CDC/NCEZID) 

4:25 Dengue Vaccines 

Introduction 

Takeda dengue vaccine (TAK-003) safety and efficacy 

Workgroup considerations 

Dr. Wilbur Chen (ACIP, WG Chair) 

Dr. Shibidas Biswal (Takeda) 

Dr. Gabriela Paz-Bailey (CDC/NCEZID) 

5:10 Varicella 

Public health impact of 25 years of varicella vaccination in the United States Dr. Mona Marin (CDC/NCIRD) 

5:30 Adjorn 

Friday, February 24, 2023 

8:00 Welcome & Introductions Dr. Grace Lee (ACIP, Chair) 

Dr. Melinda Wharton (ACIP Executive Secretary, CDC) 

8:10 COVID-19 Vaccines 

Introduction Dr. Matthew Daley (ACIP, WG Chair) 

COVID-19 vaccine safety updates: CDC Dr. Tom Shimabukuro (CDC/NCEZID) 

COVID-19 vaccine safety updates: FDA Dr. Richard Forshee (FDA) 

VaST summary Dr. Keipp Talbot (ACIP, VaST Co-Chair) 

WG interpretation and summary Dr. Evelyn Twentyman (CDC/NCIRD) 

9:30 Break 

9:45 Updates on COVID-19 hospitalizations: COVID-NET Dr. Chris Taylor (CDC/NCIRD) 

Updates to COVID-19 vaccine effectiveness in the United States Dr. Amadea Britton (CDC/NCIRD) 

Considerations for transitioning to bivalent primary series Dr. Sara Oliver (CDC/NCIRD) 

11:30 Break 

11:45 Benefit/risk for COVID-19 vaccines Dr. Megan Wallace (CDC/NCIRD) 

COVID-19 vaccines: future directions Dr. Sara Oliver (CDC/NCIRD) 

1:45 Adjorn 
Final - February 17, 2023 

Acronyms 

ARI Acute respiratory illness 

CDC Centers for Disease Control and Prevention 

CMS Centers for Medicare and Medicaid Services 

COVID-19 Coronavirus disease 2019 

EtR Evidence to Recommendations Framework 

FDA Food and Drug Administration 

GRADE Grading of Recommendations Assessment, Development and Evaluation 

HRSA Health Resources and Services Administration 

IHS Indian Health Service 

NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] 

NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID] 

NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID] 

NIAID National Institute of Allergy and Infectious Diseases 

OIDP Office of Infectious Disease and HIV/AIDS Policy 

PCV20 20-valent pneumococcal conjugate vaccine 

SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 

VaST COVID-19 Vaccine Safety Technical Work Group 

WG Work Group 

WHO World Health Organization 

VE Vaccine Effectiveness